An orally biological chemotaxis-guided hypoxia-responsive biomimetic microcapsules for visualizing multi-faceted synergistic therapy of inflammatory bowel disease

被引：0
作者：
Wang, Yifei [1 ]
Xia, Yaning [1 ]
Zhou, Mengyang [1 ]
Zhang, Yong [1 ]
Cheng, Jingliang [1 ,2 ]
Shi, Yupeng [1 ,2 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept MRI, Zhengzhou 450052, Peoples R China
[2] Funct Magnet Resonance & Mol Imaging Key Lab Henan, Zhengzhou 450052, Peoples R China
来源：
CHEMICAL ENGINEERING JOURNAL | 2025年 / 506卷
基金：
中国国家自然科学基金;
关键词：
Inflammatory bowel disease; Metal-organic frameworks; Microbial regulation; Anemia; MR imaging; PROBIOTICS; MICROBIOTA;
D O I：
10.1016/j.cej.2025.160203
中图分类号：
X [环境科学、安全科学];
学科分类号：
08 ; 0830 ;
摘要：
Oral drug delivery systems have great advantages in the treatment of enteritis. Compared to free drugs, the drug delivery system protects drugs from damage to the complex gastrointestinal environment and improves bioavailability. However, the limited accumulation of drugs in inflammatory bowel disease restricts the efficiency of oral drug delivery. Here, we propose an oral administration strategy to restore intestinal homeostasis by targeting the regulation of intestinal inflammation through biomimetic iron-tungsten nanomedicine guided by biological chemotaxis. The microcapsules introduce a lactic acid bacteria membrane giving the Fe/W-MOFs excellent resistance to the harsh gastrointestinal environment and improving their retention in the enteritis site. Furthermore, inspired by the hypoxic environment of the intestine and the symptoms of inflammatory bleeding, the microcapsules can be degraded in an anoxic response and release the corresponding iron, tungsten, and 5-ASA to achieve anemia treatment, intestinal flora regulation, and anti-inflammatory effects. It is worth noting that the effective release of iron ions can also be used as an MRI contrast agent for imaging and monitoring of enteritis treatment. Therefore, the biomimetic microcapsules can effectively and accurately reprogram the intestinal microbiome through a multi-pronged comprehensive treatment such as eliminating pathogenic bacteria, improving anemia, and anti-inflammation, bringing extraordinary advantages for diagnosing and treating DSS-induced colitis.
引用
收藏
页数：14
相关论文
共 45 条
  • [1] Chen T., Meng W., Li Y., Li X., Yu X., Qi J., Ding D., Li W., Probiotics armed with in situ mineralized nanocatalysts and targeted biocoatings for multipronged treatment of inflammatory bowel disease, Nano Lett., 24, 24, pp. 7321-7331, (2024)
  • [2] Yang J., Tan S., Ge S., Yang M., Liu H., Liu W., Zhang K., Zhang Z., Wang Z., Shi J., Liu J., Cyanobacteria–probiotics symbionts for modulation of intestinal inflammation and microbiome dysregulation in colitis, Proc. Natl. Acad. Sci., 121, (2024)
  • [3] Herbada R.S., Torres-Suarez A.I., Otero-Espinar F.J., Fraguas-Sanchez A.I., Lopez-Cabarcos E., Rubio-Retama J., Fernandez-Carballido A., Matrix tablets based on a novel poly (magnesium acrylate) hydrogel for the treatment of inflammatory bowel diseases, Int J Pharm, 608, (2021)
  • [4] Curvino E.J., Roe E.F., (2023)
  • [5] Song X., Huang Q., Yang Y., Ma L., Liu W., Ou C., Chen Q., Zhao T., Xiao Z., Wang M., Jiang Y., Yang Y., Zhang J., Nan Y., Wu W., Ai K., Efficient Therapy of Inflammatory Bowel Disease (IBD) with Highly Specific and Durable Targeted Ta2C Modified with Chondroitin Sulfate (TACS), Adv. Mater., 35, 36, (2023)
  • [6] Wang M., Huang Q., Liu M., Zhao T., Song X., Chen Q., Yang Y., Nan Y., Liu Z., Zhang Y., Wu W., Ai K., Precisely Inhibiting Excessive Intestinal Epithelial Cell Apoptosis to Efficiently Treat Inflammatory Bowel Disease with Oral Pifithrin‐α Embedded Nanomedicine (OPEN), Adv. Mater., 35, 49, (2023)
  • [7] Huang Q., Yang Y., Zhu Y., Chen Q., Zhao T., Xiao Z., Wang M., Song X., Jiang Y., Yang Y., Zhang J., Xiao Y., Nan Y., Wu W., Ai K., Oral Metal‐Free Melanin Nanozymes for Natural and Durable Targeted Treatment of Inflammatory Bowel Disease (IBD), Small, 19, 19, (2023)
  • [8] Punchard N.A., Greenfield S.M., Thompson R.P., Mechanism of action of 5-arninosalicylic acid, Mediat. Inflammat., 1, pp. 151-165, (1992)
  • [9] Schirmer M., Garner A., Vlamakis H., Xavier R.J., Microbial genes and pathways in inflammatory bowel disease, Nat. Rev. Microbiol., 17, 8, pp. 497-511, (2019)
  • [10] Lavelle A., Sokol H., Gut microbiota-derived metabolites as key actors in inflammatory bowel disease, Nat. Rev. Gastroenterol. Hepatol., 17, 4, pp. 223-237, (2020)
12345